116 related articles for article (PubMed ID: 36436754)
1. YM155 inhibits neuroblastoma growth through degradation of MYCN: A new role as a USP7 inhibitor.
Li X; Yang F; He N; Zhang M; Lv Y; Yu Y; Dong Q; Hou X; Hao Y; An Z; Zhang H; Yang Z; Zhai H; Guo D; Cao Z; Jiang VC; Chen Y
Eur J Pharm Sci; 2023 Feb; 181():106343. PubMed ID: 36436754
[TBL] [Abstract][Full Text] [Related]
2. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
3. USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation.
Le Clorennec C; Lee K; Huo Y; Zage PE
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762082
[TBL] [Abstract][Full Text] [Related]
4. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma.
Tavana O; Li D; Dai C; Lopez G; Banerjee D; Kon N; Chen C; Califano A; Yamashiro DJ; Sun H; Gu W
Nat Med; 2016 Oct; 22(10):1180-1186. PubMed ID: 27618649
[TBL] [Abstract][Full Text] [Related]
5. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
[TBL] [Abstract][Full Text] [Related]
6. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.
Lampis S; Raieli S; Montemurro L; Bartolucci D; Amadesi C; Bortolotti S; Angelucci S; Scardovi AL; Nieddu G; Cerisoli L; Paganelli F; Valente S; Fischer M; Martelli AM; Pasquinelli G; Pession A; Hrelia P; Tonelli R
J Exp Clin Cancer Res; 2022 Apr; 41(1):160. PubMed ID: 35490242
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression.
Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF
J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547
[TBL] [Abstract][Full Text] [Related]
8. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
9. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
10. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
Lamers F; Schild L; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Mar; 48(5):763-71. PubMed ID: 22088485
[TBL] [Abstract][Full Text] [Related]
11.
Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
[TBL] [Abstract][Full Text] [Related]
12. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
13. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
[TBL] [Abstract][Full Text] [Related]
14. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
15. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.
Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y
J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476
[TBL] [Abstract][Full Text] [Related]
16. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
17. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.
Henriksen JR; Haug BH; Buechner J; Tømte E; Løkke C; Flaegstad T; Einvik C
BMC Dev Biol; 2011 Jan; 11():1. PubMed ID: 21194500
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
19. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
20. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
